3 results  1 of 1 

1 Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
Jiyun Lee, Seock-Ah Im, Gun Min Kim, Kyung Hae Jung, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Hee Kyung Ahn, Yeon Hee Park
Cancer Res Treat.2021;53(3):695-702.   Published online 2020 December 17     DOI: http://dx.doi.org/10.4143/crt.2020.1246
      
2 Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions
Jieun Lee, Hyung Soon Park, Hye Sung Won, Ji Hyun Yang, Hee Yeon Lee, In Sook Woo, Kabsoo Shin, Ji Hyung Hong, Young Joon Yang, Sang Hoon Chun, Jae Ho Byun
Cancer Res Treat.2021;53(2):409-423.   Published online 2020 October 28     DOI: http://dx.doi.org/10.4143/crt.2020.451
      
3 Acute Lymphoblastic Leukemia in a Patient Treated with Letrozole and Palbociclib
Jin Hyun Park, Hyunkyung Park, Ki Hwan Kim, Jin-Soo Kim, In Sil Choi, Eun Youn Roh, Ji Eun Kim, Mee Soo Chang
J Breast Cancer.2020;23(1):100-106.   Published online 2019 November 13     DOI: http://dx.doi.org/10.4048/jbc.2020.23.e1
      

 1 of 1